Investors Encouraged to Join Inovio Pharmaceuticals Securities Fraud Class Action Lawsuit

Investors Invited to Lead Class Action Against Inovio Pharmaceuticals

The Schall Law Firm has issued a reminder for investors affected by potential misconduct by Inovio Pharmaceuticals, Inc., to consider joining a class action lawsuit. This internal lawsuit accuses the company of violating both the Securities Exchange Act and related SEC rules, potentially opening the door for affected investors to recover losses incurred during a specific time frame.

Overview of the Case

Inovio Pharmaceuticals, a company publicly traded under NASDAQ symbol INO, is currently facing serious allegations concerning the integrity of its public statements and adherence to regulatory standards. Specifically, these allegations stem from the period between October 10, 2023, and December 26, 2025. Investors who bought into the company's stocks during this time frame are strongly encouraged to reach out to the Schall Law Firm, as they may have a valid claim.

The Allegations

The complaint filed in this case suggests that Inovio made numerous misleading statements to the market regarding the abilities of its CELLECTRA device and the anticipated filing of its biological license application (BLA) for drug INO-3107. Crucially, the suit claims that Inovio faced significant manufacturing deficiencies that impacted the production and efficacy of its device, thereby contradicting their public assertions.

Inovio was reportedly not on track to file the BLA as previously stated, causing skepticism not only about the approval process from the FDA but also about the strength of evidence that the company could present to justify a priority review or accelerated approval. Under these circumstances, the company's public disclosures are argued to have been fundamentally misleading, which resulted in financial damages to investors when the truth surfaced.

What Investors Should Do

Investors who believe they suffered losses due to the company’s misleading claims should consider taking action by focusing on their rights within this lawsuit. The Schall Law Firm is committed to representing shareholders who have been harmed by the alleged dishonest conduct of corporations like Inovio. Those interested can contact Brian Schall directly for a complimentary consultation, where they’ll be briefed on their legal rights and options.

Important Reminders

It’s critical for affected shareholders to act swiftly, as the window for participating in this class action is open until April 7, 2026. Until the class is certified, potential participants are not yet represented by an attorney and would not be included in legal actions if they remain inactive.

Conclusion

In light of the troubling allegations made against Inovio Pharmaceuticals, shareholders have a crucial opportunity to join forces via a class action lawsuit to potentially recoup losses. With the backing of the Schall Law Firm, affected investors are urged to make their voices heard and to participate before the deadline expires. By coming forward, shareholders can play a proactive role in seeking justice and accountability within the realm of securities trading.